Drug resistance-associated marker lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma

Journal of the National Cancer Institute

Volumn 87, Issue 16, 1995, Pages 1230-1237

  Lzquierdo, Miguel A ^a   Zee, Ate G J van Der ^b   Vermorken, Jan B ^a   Valk, Paul Van Der ^a   Beliën, Jeroen A M ^a   Giaccone, Giuseppe ^a   Scheffer, George L ^a   Flens, Marcel J ^a   Pinedo, Herbert M ^a   Kenemans, Peter ^a   Meijer, Chris J L M ^a   Vries, Elisabeth G E de ^b   Scheper, Rik J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE ASSOCIATION; GENE EXPRESSION; GENETIC MARKER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIDRUG RESISTANCE; OVARY CARCINOMA; PREDICTION; PROGNOSIS;

ANTIBODIES, MONOCLONAL; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN; IMMUNOENZYME TECHNIQUES; MIDDLE AGE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RIBONUCLEOPROTEINS; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0029081126     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/87.16.1230     Document Type: Article

References (49)

1. Boring CC, Squires TS, Tong T: Cancer statistics, 1993. CA Cancer J Clin 43:7-26, 1993
2. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, et al: Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 27:1367-1372, 1991
3. Ozols RF: Treatment of ovarian cancer current status. Semin Oncol 21:19, 1994
4. Johnson SW, Ozols RF, Hamilton TC: Mechanisms of drug resistance in ovarian cancer. Cancer 71(2 Suppl):644-649, 1993
5. Goldstein LJ, Pastan I, Gottesman MM: Multidmg resistance in human cancer. Crit Rev Oncol Hematol 12:243-253, 1992
6. Beck WT, Danks MK: Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Semin Cancer Biol 2:235-244, 1991
7. van der Zee AG, van Ommen B, Meijer C, et al: Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy. BrJ Cancer 66:930-936, 1992
8. Bissett D, McLaughlin K, Kelland LR, et al: Cisplatin-DNA damage recognition proteins in human tumour extracts. Br J Cancer 67:742-748, 1993
9. Arao S, Suwa H, Mandai M, et al: Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res 54:1355-1359, 1994
10. van der Zee AG, Hollema H, Suurmeijer AJ, et al: Value of P- glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 13:70-78, 1995
11. Cole SP, Bhardwaj G, Gerlach JH, et al: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line [see comment citation in Medline]. Science 258:1650-1654, 1992
12. Grant CE, Valdimarsson G, Hipfner DR, et al: Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54:357-361, 1994
13. Zaman GJ, Flens MJ, van Leusden MR, et al: The human multidrug resistance-associated protein (MRP) is a plasma membrane drug efflux pump. Proc Natl Acad Sci U S A 91:8822-8826, 1994
14. Cole SP, Sparks KE, Fraser K, et al: Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902-5910, 1994
15. Scheper RJ, Broxterman HJ, Scheffer GL, et al: Overexpression of a M(r) 110, 000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res53:1475-I479, 1993
16. Izquierdo MA, van der Valk P, Scheffer GL, et al: Distribution in normal human tissues and tumors of a 110 kD protein associated with non P- glycoprotein multidrug resistance. Proc Am Assoc Cancer Res 34:Abstr 1849, 1993
17. Scheffer GL, Wijngaard PL, Glens MJ, et al: The drug resistance related protein LRP is the human major vault protein. Nature Med 1:578-582, 1995
18. Kedersha NL. Rome LH: Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA. J Cell Biol 103:699-709. 1986
19. Rome L, Kedersha N, Chugani D: Unlocking vaults: organelles in search of a function. Trends Cell Biol 1:47-50, 1991
20. International Federation of Gynecology and Obstetrics: Changes in definitions of clinical staging for cancer of the cervix and ovary. Am J Obstet Gynecol 156:263-264, 1987
21. Serov SF, Scully RE, Sobin LH: Histological Typing of Ovarian Tumours. Geneva: WHO, 1973, pp 17-18
22. Sorbe B, Frankendal B, Veress B: Importance of histologic grade in the prognosis of epithelial ovarian carcinoma. Obstet Gynecol 59:576-582, 1982
23. World Health Organization: WHO Handbook on Reporting Results of Cancer Treatment. Geneva: WHO, 1979
24. Hamada H, Tsuruo T: Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells revealed by monoclonal antibodies. Proc Natl Acad Sci U S A 83:7785-7789, 1986
25. Scheper RJ, Bulte JW, Brakkee JG, et al: Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance. Int J Cancer 42:389-394, 1988
26. Weinstein RS, Kuszak JR, Kluskens LF, et al: P-glycoproteins in pathology: the multidrug resistance gene family in humans. Hum Pathol 21:3448, 1990
27. Flens MJ, Izquierdo MA, Scheffer GL, et al: Immunochemical detection of the multidrug resistance-associated MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res 54:4557-4563, 1994
28. Akiyama SI, Fojo A, Hanover JA, et al: Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet 11:117-126, 1985 '
29. Zijlstra JG, de Vries EG, Mulder NH: Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 47:1780-1784, 1987
30. Kuiper CM, Broxterman HJ, Baas F, et al: Drug transport variants without P-glycoprotein overexpression from a human squamous lung cancer cell line after selection with doxorubicin. J Cell Pharmacol 1:35-41, 1990
31. Chan HS, Haddad G, Thomer PS, et al: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma [see comment citation in Medline], N Engl J Med 325:1608-1614, 1991
32. Cordell JL, Falim B, Erber WN, et al: Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline "phosphatase" and monoclonal anti-alkaline phosphatase (APAAP complexes). J His- tochem Cytochem 32:219-229, 1984
33. Dixon WJ, ed: BMDP Statistical Software Manual. Los Angeles: Univ Calif Press, 1990
34. Reiss JL: Statistical Methods for Rates and Proportions. New York: John Wiley & Sons, 1981
35. Daly LE, Bourke GJ, McGilvray J: Interpretation and Uses of Medical Statistics, 4th ed. Oxford: Blackwell, 1991
36. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
37. Mantel N: Evaluation of survival data and two new rank order statistics arising in its considerations. Cancer Chemother Rep 50:163-170, 1966
38. Brookmeyer R, Crowley J: A confidence interval for the median survival time. Biometrics 38:29-41, 1982
39. Cox DR, Oakes D: Analysis of Survival Data. London: Chapman & Hall, 1984
40. Hamaguchi K, Godwin AK, Yakushiji M, et al: Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 53:5225-5232, 1993
41. Futscher BW, Abbaszadegan MR, Domann F, et al: Analysis of MRP mRNA m mitoxantrone-selected, multidrug-resistant human tumor cells. Biochem Pharmacol 47:1601-1606, 1994
42. List AF, Spier CS, Abbaszadegan M, et al: Non-P-glycoprotein (PGP) mediated multidrug resistance (MDR): identification of a novel drug resistance phenotype with prognostic relevance in acute myeloid leukemia (AML). Blood 82:abstr 443, 1993
43. Chugani DC, Rome LH, Kedersha NL: Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. J Cell Sci 106(Pt l):23-29, 1993
44. Rout MP, Wente SR: Pores for thought: nuclear pore complex proteins. Trends Cell Biol 4:357-365, 1994
45. Schuurhuis GJ, Broxterman HJ, de Lange JH, et al: Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. BrJ Cancer 64:857-861, 1991
46. Dietel M, Arps H, Lage H, et al: Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res 50:6100-6106, 1990
47. Holzmayer TA, Hilsenbeck S, Von Hoff DD, et al: Clinical correlates of MDR1 (P-glycoprotein) gene expression m ovarian and small-cell lung carcinomas [see comment citation in Medline]. J Natl Cancer Inst 84:14861491, 1992
48. Edlitschky G, Leier I, Buchholz U, et al: ATP-dependent transport of jlutathione S-conjugates by the multidmg resistance-associated protein, lancer Res 54:4833-4836, 1994
49. dilller M, Meijer C, Zaman GJ, et al: Overexpression of the gene encod- ng the multidmg resistance-associated protein results in increased ATP- lependent glutathione S-conjugate transport. Proc Natl Acad Sci U S_A 1:13033-13037, 1994